A total of 751 participants were randomized in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg)

dose reduction required if eGFR 3044 ml/min/1.73m Rybelsus (semaglutide) prescribing criteria are more restrictive: Licensed for type 2 diabetes management, not for weight loss as a standalone indication NICE NG28 recommends GLP-1 receptor agonists as an option for adults with type 2 diabetes when: For weight management specifically , a different formulation of semaglutide (Wegovy, subcutaneous injection) has been approved by NICE (TA875) for adults with: BMI 35 kg/m (or 32.5 kg/m in people of South Asian, Chinese, Black African, or Black Caribbean ethnicity) or BMI 3034.9 kg/m (or 27.5 kg/m in people from the above ethnic groups) with at least one weight-related comorbidity And participation in a specialist weight management service Access to Wegovy is subject to local commissioning arrangements and availability through specialist weight management services, as outlined in NICE TA875

As with all GLP-1 receptor agonists, this is a prescription-only medication. The regulator emphasised that patients should follow the instructions in the Patient Information Leaflet carefully to ensure the treatment works effectively
Button: Get Started *Medication supplied only through licensed 503A/503B pharmacies
Natural, minimally processed cheeses provide sodium alongside calcium, potassium, and magnesiumminerals that work synergistically to regulate blood pressure